Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response

202160 citationsJournal Articlebronze Open Access

Authors

Qing Zhou · Medical University of Graz

Simon P. Gampenrieder · Paracelsus Medical University

Sophie Frantal · Austrian Breast & Colorectal Cancer Study Group

Gabriel Rinnerthaler · Paracelsus Medical University

Christian F. Singer · Comprehensive Cancer Center Vienna

Daniel Egle · Innsbruck Medical University

Georg Pfeiler · Comprehensive Cancer Center Vienna

Rupert Bartsch

Abstract

Overall, our results demonstrate that the detection and persistence of ctDNA at MT may have the potential to negatively predict response to neoadjuvant treatment and identify patients who will not achieve pCR or be classified with RCB II/III.

Topics & Keywords

Cancer Genomics and Diagnostics Cancer Cells and Metastasis Breast Cancer Treatment Studies

Publication Details

Published in: Clinical Cancer Research

Volume 28, Issue 4, pp. 697-707

DOI: 10.1158/1078-0432.ccr-21-3231

Field-Weighted Citation Impact: 2.89

Command Palette

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response

Authors

Abstract

Topics & Keywords

Publication Details